Trial
NCT04466475
Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Cancer Institute (NCI); National Institutes of Health (NIH)
Condition
Plasma Cell Myeloma
Intervention
Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10
Why stopped
NIH terminated funding. Study was closed before any participants were enrolled.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-01-31